For example, the EML4-ALK fusion has been identified in at least 2% of patients with NSCLC [8]; this fusion is well studied in the literature and different generations of drugs have been developed to benefit patients with EML4-ALK. Here, EML4 is linked to non-small cell lung carcinoma.